Treatment strategies for metastatic prostate cancer Oliver Hakenberg Department of Urology, Rostock University.

Slides:



Advertisements
Similar presentations
Oncologic Drugs Advisory Committee
Advertisements

ASCO G.U Lawrence H. Einhorn.
Más es posible: CPRC con Metástasis Óseas Sintomáticas Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Complutense.
Castrate-resistant prostate cancer (CRPC)
The Role of the Medical Oncologist in the Treatment of Prostate Cancer
Natural History of Prostate Cancer Local therapy Androgen deprivation therapy (ADT) Therapies after ADT Death ADT mCRPC post- docetaxel mCRPC symptomatic.
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,
CARCINOMA DELLA PROSTATA. PROSTATE CANCER Prostate Anatomy.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Is there a role for adjuvant/neoadjuvant chemotherapy in High risk prostate cancer? Giuseppe Procopio Fondazione IRCCS Istituto Nazionale Tumori Milano.
1 NDA / S012 CASODEX (bicalutamide) 150 mg FDA Review Division of Reproductive and Urologic Drug Products (DRUDP)
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival in patients with metastatic CRPCa who have progressed.
Drug Treatment of Metastatic Breast Cancer
6 months versus 12 months of adjuvant trastuzumab for patients with HER2- positive early breast cancer (PHARE): a randomised phase 3 trial Speaker: 陳鴻明.
Renal Safety of Zoledronic Acid in Patients With Breast Cancer.
How should we sequence therapy? Dipartimento Scienze Radiologiche, Oncologiche e Anatomo Patologiche; Oncologia B. “Sapienza” Università di Roma Enrico.
Howard M. Sandler, MD University of Michigan Medical School
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Treatment Options for Docetaxel refractory patients
Low dose chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration resistant prostate cancer.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
Phase III studies of Xeloda® in colorectal cancer (CRC)
Immunotherapeutic Approaches in Castration Resistant Prostate Cancer (CRPC) Philip Kantoff, MD Chief, Division of Solid Tumor Oncology Dana-Farber Cancer.
Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
Prostate Support Group Dr Duncan McLaren Consultant Oncologist.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
Castration-Resistant Metastatic Prostate Cancer: Novel Therapeutics Robert Dreicer, M.D., M.S., FACP Chairman Department of Solid Tumor Oncology Taussig.
CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.
Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic.
J Clin Oncol 31: © 2013 by American Society of Clinical Oncology GASTROENTEROLOGY 2012;143:897–912. Journal conference.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Graph paper template R2 이지훈 / Prof. 맹치훈 Lancet Oncol 2012; 13:
Matthew Raymond Smith, MD, PhD Professor of Medicine Harvard Medical School Program Director, Genitourinary Oncology Massachusetts General Hospital Cancer.
CCO Independent Conference Coverage
Abiraterone Changes in Landscape of Advanced Prostate Cancer
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Pazopanib: the role in the treatment of mRCC
LUX-Lung 3 clinical trial
CCO Independent Conference Coverage
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
The future of our patients already treated with first line chemotherapy First of all, I would like to take this opportunity to thank the Mediterranean.
CCO Independent Conference Coverage
WHEN IS CHEMOTHERAPY INDICATED FOR HORMONE-NAÏVE PROSTATE CANCER
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
Use of Ipilimumab in Metastatic CRPC That Progressed After Docetaxel
Alena Kreychman Xofigo.
N.N. Alexandrov National Cancer Centre
SYSTEMIC THERAPY OF PROSTATE CANCER
Bergh J et al. SABCS 2009;Abstract 23.
Prostate Cancer Management: What Does the Future Hold?
FDA Approvals for Systemic Treatment of Prostate Cancer in 2018
Chemotherapy Options for Advanced Prostate Cancer
First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.
Presentation transcript:

Treatment strategies for metastatic prostate cancer Oliver Hakenberg Department of Urology, Rostock University

prostate cancer is hormone-dependent LHRH = luteinising hormone releasing hormone LH = luteinising hormone ACTH = adrenocorticotropal hormone testosterone pineal gland cortisole adrenal androgens Prostata testes prolactine adrenal glands hypothalamus LH ACTH LHRH estrogens orchidectomy antiandrogens LHRH analogues antiandrogens

Pathologic fractures after orchidektomy n=235 Daniell et al, J Urol 1997 orchidectomy no orchidectomy years % cumulative incidence of osteoporotic fractures

Immediate androgen ablation permanent –advanced metastatic disease M+ –locally advanced, if androgen ablation is the only treatment option adjuvant/temporary –radical prostatectomy with positive nodes (pN+) –adjuvant with radiotherapy in intermediate and high risk disease

Early or delayed androgen ablation? Messing et al, Lancet Oncology 2006 RPE pN+ early vs observation/delayed randomized n= 98 Overall survival Cancer-specific survival

androgen ablation ↓ gonadal testosterone 10-30% serum androgens from other sources Adrenal cortex: DHEA + androstendione → transformed to testosterone in periphery (including prostate) progression after xx months → hormone resistant

hormone resistance? de novo intratumoral androgen synthesis in progressive CRPC → maintenance of intracellular andogen levels → androgen receptor (AR) stimulation despite low serume testosterone „castration-resistant prostate cancer“ = CRPC Locke et al, Cancer Res 2008

3 new developments autologous vaccine sipuleucel-T (IMPACT) –mCRPC docetaxel-naive (85%) –improved OS vs placebo cabazitaxel (TROPIC) –mCRPC doxetaxel-refractory –improved OS vs mitoxantrone arbiraterone –hormonal principle in CPRC Kantoff et al, N Engl J Med 2010 De Bono et al, Lancet 2010

Arbiraterone inhibition of testosterone biosynthesis arbiraterone acetate inhibits –C 17,20 lyase –17  hydroxylase –Inhibition selective & irreversible adrenals, testes, prostate cancer cells arbiraterone acetate: prodrug good oral bioavailability Development of resistance

Sonpavde et al, Eur Urol 2011

Attard et al, Cancer Res 2009

Study data: arbiraterone in CRPC phase I –chemotherapy-naive CRPC patients phase-II NCT –progression after docetaxel phase-III NCT –progression after docetaxel phase III NCT –asymptomatic, low metastatic load in chemotherapy-naive patients

phase I n=21 chemo-naive, CRPC –12/21 with PSA↓>50% and > 3 months –of which in 6/12 PSA↓ > 90% –PR (RESIST) in 5/8 patients and ↓analgesic medication –no grade grade 3/4 toxicity Attard et al, J Clin Oncol 2008

phase II a chemotherapy-naive CRPC patients PSA↓> 50% in 70-80% of patients RESIST response 37.5% median time to PSA-rise 225 days dexamethasone at progression with arbiraterone: further PSA↓>50% in 33% Attard et al, J Clin Oncol 2009

phase II b n= 47 docetaxele-pretreated CRPC PSA↓> 50% in 51% of patients 35 with RESIST –PR 17% –SD 66% 23% ECOG improvement Reid et al, J Clin Oncol 2009

Phase II c docetaxele-pretreated CRPC better efficacy without ketoconazole pretreatment –53% vs 33% PSA-response without/with –31% vs 4% PSA↓>90% without/with ketoconazole –median time to progression 198 vs 99 days with/without ketoconazole Danila et al, J Clin Oncol 2009

phase III (COU-AA-301) n=1195 docetaxel-refractory CRPC arbiraterone vs placebo 2:1 randomisation stratification –ECOG 0-1 vs 2 –prior chemotherapy schedules 1 vs 2 –pain score –type of progression: PSA vs XR

OS 14.8 vs 10.4 months TTP 10.2 vs 6.6 months rPFS 5.6 vs 3.6 months PSA RR 29.1% vs 5.5% toxicity –hyperhydration 2.3% vs 1.0% –hypokalaemia 3.8% vs 0.8% –hypertension 1.3% vs 0.3% –cardiopulmonary 4.1% vs 2.3% phase III (COU-AA-301) 1.interim analysis 2010 De Bono et al, ESMO 2010

arbiraterone n=1195 docetaxel resistant 2:1 randomisation –arbiraterone 1000 mg + 5 mg prednisone vs –placebo + 5 mg prednisone overall survival –arbiraterone 14.8 months –placebo 10.9 months de Bono et al, N Engl J Med 2011

treatment options for metastatic prostate cancer hormonal –androgen ablation orchidectomy LHRH-antagonists or –agonists androgen blockers –androgen conversion blocker arbiraterone chemotherapy –docetaxel –cabazitaxel bisphosphonates pain treatment nuclear medical tretament: samarium, strontium best supportive care

Prognosis of metastatic prostate cancer initial response to androgen ablation > 80% progression in 50-60% of patients within 2 years after that median survival months 5 year survival rate with M+ oss 20%

androgen antagonists steroidal –cyproterone acetate non-steroidal –bicalutamide –flutamide –nilutamide

proportion without event time (months) bicalutamide 150 mg + standard care Placebo + standard care 54 reduction of the risk of PSA progression by 59 % Kaplan-Meier curve of time to PSA progression HR 0.41; 95% CI 0.38, 0.45; p<< Early Prostate Cancer Program

natural course of prostate cancer after radical prostatectomy and PSA recurrence (n= 311) years PSA recurrence distant metastases death of prostate cancer Pound et al., JAMA 1999

Hormone-independent prostate cancer hormone independent hormone sensitive hormone dependent hormone withdrawal hormone naive hormone independent

definition of castration-resistant prostate hormone- refractory prostate cancer (HRPC) serume testosteron at castration level secondary hormonal treatment without effect ketoconazole estrogens rising PSA at 3 consecutive measurements at intervals of 1 week at leastt with continued LHRH – blockade and after witrhdrawal of androgen blocker lowest PSA limit: 0.4 ng/ml

Chemotherapy for prostate cancer? Reviews response rates 1985: (17 Studien)6,5 % M. Eisenberger, J Clin Oncol : (26 Studien)8,7 % Yagoda & Petrylak, Cancer 1993 P.Walsh 1995: „This is going to be an extremely short discussion. Not only does it fail to cure the cancer, it doesn’t even prolong survival to any significant degree, and its side effects only add to the unpleasantness of having prostate cancer.“

phase III: mitoxantrone (12mg/m²) + prednisone (10mg/d) vs. prednisone (10mg/d) –161 patients. (80 M+P; 81 P) phase III: mitoxantrone (14mg/m²) + hydrocortisone (40mg/d) vs. hydrocortisone (40mg/d) –242 patients results –improvement in pain –improvement in quality of life –duration of response 5-7 months –no influence on survival chemotherapy for prostate cancer – mitoxantrone for HRPC? Tannock et al Kantoff et al mitoxantrone approved by FDA as standard chemotherapy in HRPC

docetaxel TAX 327 SWOG 9916 both studies showed overall survival advantage for docetaxel Petrylak, N Engl J Med 2004 Tannock, N Engl J Med 2004

20% 40% 60% 80% 100% months D + E M + P no. at Risk median survival (months) HR: 0.80 (95% CI 0.67, 0.97), p = 0.01 med. F/U: 1 J docetaxel chemotherapy overall survival SWOG 9916 no (n) died Petrylak et al, N Engl J Med 2004

SWOG Petrylak J NCI 2006

Survival in subgroups docetaxel 3 weekly vs mitoxantrone Intent to Treat age < 65 age ≥ 65 age ≥ 75 pain no pain yes KPS ≥ 80 KPS ≤ 70 hazard ratio in favour of docetaxel mitoxantrone Tannock et al, N Engl J Med 2004

Cochrane Review chemotherapy of HRPC n=6929 patients; 47 studies investigated substances: –EMP –docetaxel –5-FU –cyclophosphamide –doxorubicine –mitoxantrone –vinorelbine Shelley M, Harrison C et al. Cochrane Database Syst Rev 2006

Cochrane Review PSA response (>50%): –EMP48% –docetaxel52% –5-FU20% –cyclophosphamiden.d. –doxorubicine50% (CAVE: only 1 study!) –mitoxantrone 33% –vinorelbinen.d. Shelley M, Harrison C et al. Cochrane Database Syst Rev 2006

only DOC => overall survival ↑ (<2.5 months) pain ↓DOC > Mit + Pred quality of life ↑ DOC > Mit + Pred results authors‘ conclusion: „At the present time this* probably represents the best chemotherapeutic regime available for men with HRPC“ *- docetaxel q3w Shelley M, Harrison C et al. Cochrane Database Syst Rev 2006

secondary hormone manipulation or chemotherapy? secondary hormone manipulation chemotherapy CALGB9583SWOG 9916TAX-327 AAW + Ketokonazol EMP docetaxel vs MP DP q3w vs DP q1w vs MP n overall survival in better arm 16.7 months17.5 months18.9 months overall survival in worse arm 15.3 months15.6 months16.5 months Bellmunt, Eur Urol Suppl 2009

open questions when to start with chemotherapy? should asymptomatic M+ patients be treated? how long to continue treatment? secondary treatment? intermittent chemotherapy? re-exposition?

Early vs late chemotherapy? for –benefit established for other entities (breast cancer, colorectal cancer) –lower tumour mass –treatment prolongs survival against –toxicity vs unreliable response –early induction of chemotherapy-refractory state –outcome is not influenced since no difference in survival between symptomatic vs asymptomatic patients (TAX327)

forms of HRPC indications for starting with chemotherapy only rising PSA asymptomatic, low metastatic load asymptomatic, large metastatic load symptomatic metastases  no indication PSA doubling time?  individual decision inclusion in study?  yes

Estimating the prognosis in CPRC PSA doubling time günstig –TAX 327:PSA-DT > 55 Tage –Oudard et al:PSA-DT > 45 Tage Armstrong et al, Clin Cancer Res 2007 Oudard et al, Ann Oncol 2007

Armstrong, A. J. et al. Clin Cancer Res 2007;13: nomographic estimation

rising PSA under chemotherapy… often initiial PSA flare-up no negative influence on survival, unless there are signs of clinical progression => minimum of 8 weeks treatment before deciding to discontinue ! Olbert Anticancer Drugs 2006

Copyright restrictions may apply. Thuret et al, Ann Oncol 2008 PSA-Flare with chemotherapy in patients with subsequent PSA response or stable disease PSA values normalized to a starting point of 100 ng/ml

Chemotherapy until… best number of cycles unknown TAX 327: mean of 8 cycles but: chronic toxicity increases with no of cycles intermittend chemotherapy?

When to discontinue chemotherapy…? definite worsening of physical state PSA doubling time < 3 Monate slow PSA increase: - discontinue if clinically progressive Miller et al. Akt Urol 2006

First line chemotherapy docetaxel Mono (75mg/m² KO d1, q21d) Second line chemotherapy options: –docetaxel (M  D)PR: 44-85% –docetaxel weekly PR: 72% –mitoxantrone (D  M)PR: 6-15% –satraplatin (SPARC) –cabazitaxel

Cabazitaxel second line overall survival de Bono et al, Lancet 2010 open label, randomized, n= 755 CPRC patients with progression on docetaxel cabazitaxel 25 mg/m 2 q3w + prednisone 10 mg p.o. daily vs mitoxantrone 12 mg/m 2 q3w i.v.+ prednisone 10 mg p.o. daily mean survival overall CABA15.1 months MITO12.7 months

Cabazitaxel second line progression-free survival de Bono et al, Lancet 2010

ketoconazole 200 or 400 mg tid p.o. ketoconazole + hydrocortisone replacement doses mg p.o. n= 114 response depends on disease burden Keizman et al, Prostate 2010

Beltran et al, Eur Urol 2011

Hypothetical calculation Future prognosis of metastatic prostate cancer? initial response to androgen ablation > 80% progression in 50-60% of patients within 2 years after that median survival months + 4 months with docetaxel + 4 months with cabazitaxel + 4 months with arbiraterone

„This will buy you three months“

Rostock